期刊文献+

150例老年非小细胞肺癌临床特点与预后因素分析 被引量:14

Prognostic Factors and Clinical Features of 150 Elderly Patients with Non-Small Cell Lung Cancer
原文传递
导出
摘要 目的:分析老年非小细胞肺癌患者的临床特点和预后因素。方法:回顾性分析150例老年(年龄≥70岁)非小细胞肺癌患者临床资料。采用单、多因素分析评估患者临床病理特征和预后因素。结果:150名患者中,临床分期为Ⅲ-Ⅳ的晚期肺癌的患者例数为135例。约4/5患者是男性并且超过70%男性患者有吸烟史。首发症状主要表现为咳嗽、咳痰,其中20%患者伴发慢性肺部疾病。单因素分析,经过综合治疗或者单纯手术治疗患者中位生存时间(22月,29月)均高于仅接受最佳支持治疗的患者(10月,P<0.05)。女性患者(n=32)中位生存时间高于男性(n=118),分别为22月,14月(P<0.05)。80岁以上组患者中位生存时间(4月)明显下降,与70-75岁(16月),76-80岁组(13月)之间具有显著性差异(P<0.01)。6月内体重减轻(>5%)2年生存率明显低于于体重未减轻者,分别为12.07%,48.91%(P<0.01)。ECOG评分≤2分2年生存率明显优于ECOG评分>2分,分别为41.18%,20.83%(P<0.05)。多因素分析显示,体重减轻超过5%(HR=34.907,P<0.01)、年龄大于80岁(HR=10.91,P<0.01)和仅接受最佳支持治疗(HR=6.074,P<0.05)都是影响预后的独立因素。结论:老年非小细胞肺癌接受治疗可获益,女性,年龄相对较小,ECOG评分≤2分,接受手术治疗以及综合治疗者生存期较长,预后较好,体重减轻和仅接受最佳支持治疗患者预后差。 Objective: To analyze prognostic factors and clinic pathological features of elderly patients with nonsmall cell lung cancer(NSCLC).Methods: A total of 150 elderly NSCLC patients(age ≥70 years) were retrospectively reviewed.The clinic pathological features and prognostic factors were evaluated by univariate and multivariate analysis.Results: Among the 150 cases with median age of 73 years,advanced lung cancer(clinical stage of Ⅲa-Ⅳ) accounted for 90% of the cases.118 patients were males and 70% of all were smokers.The onset symptoms were cough,sputum,etc.20% patients had chronic lung disease.Of the 150 patients,133 received chemotherapy,radiotherapy or surgery,the rest 17 received best supportive care(BSC) therapy.The median survival time of multimodality therapy group(22 months) and single surgical group(29 months) were significantly higher than in BSC group(10 months, P 0.05).The median survival time of female patients was 22 months,higher than that of males’patients(14 months,P 0.05).The older patients had the lower survival rate,especially for who’re older than 80.The 2-years survival rate were 12.07% and 48.91%(P 0.01) respectively in group that lose weight more than 5% in 6 months and group that lose weight less than 5%.The 2-years survival rate in ECOG≤2 group was 41.18% versus 20.83% in ECOG 2 group(P 0.05).Multivariate analysis of prognostic factors using COX’s proportional hazard model showed that weight loss more than 5%,older than 80 years,BSC-treatment-only were the independent prognostic factors.Conclusion: Female, relatively young patients,ECOG≤2 and multimodality treatment were beneficial prognostic factors in elderly NSCLC patients.The elderly patients tend to have longer life expectance when diagnosed in early stage and with good performance status,whereas resection and multidisciplinary treatments may prolong the survival time.
出处 《武汉大学学报(医学版)》 CAS 北大核心 2013年第3期372-376,共5页 Medical Journal of Wuhan University
基金 湖北省自然科学基金杰出青年基金资助项目(编号:2008CDB126)
关键词 肺肿瘤 老年医学 生存 预后 Lung Neoplasm Gerriatrics Survival Prognosis
  • 相关文献

参考文献11

  • 1Dela Cruz CS, Tanoue LT, Matthay RA, et al. Lung cancer: epidemiology, etiology, and prevention [J]. Clin Chest Med,2011,32(4) 605-644.
  • 2Molina JR, Yang P, Cassivi SD, et al. Non-small cell lung cancer epidemiology, risk factors, treatment, andsurvivorship[J]. Mayo Clin Proc, 2008, 83 (5) : 584- 594.
  • 3Wakelee HA, Dahlberq SE, Brahmer JR, et al. Differen- tial effect of age on survival in advanced NSCLC in women versus men Analysis of recent Eastern Cooper- ative Onconlogy Group(ECOG) studies, with and with- out bevacizumab[J]. Lung Cancer, 2012, 76 (a): 410- 415.
  • 4Schild SE,Stella PJ, Brooks BJ, et al. Results of com- bined modality therapy for limited stage small cell lung carcinoma in the elderly[J]. Cancer, 2005,10a (11): 2 349-2 352.
  • 5De Ruysscher D, Pijls-Johannesma M, Vansteenkiste J, et al. Systematic review and meta-analysis o{ ran- domised, controlled trials of the timing of chest radio- therapy in patients with limited-stage, small-cell lung cancer[J]. Ann Oncol, 2006,17 (4) : 543-552.
  • 6Baunemann Ott CL, Ratna N, Prayag R, et al. Surviv- al and treatment patterns in eldly patients with advant- ed Non-small-cell lung cancer in manitoba[J]. Current Oncology, 2011,18(5) :e238-e242.
  • 7Forrest LM, McMillan DC, McArdle CS, et al. A pro- spective longitudinal study of performance status, an in- flammation-based score(GPS) and survival in patients with inoperableNon-small-cell lung cancer [J]. British Journal of Cancer,2005, 921 834-1 836.
  • 8Wu CH, Fan WC, Chen YM, et al. Second-line thera- py for elderly patients with non-small cell lung cancer who failed previous chemotherapy is as effective as for younger patients[J]. J Thorac Oncol, 2010,5 (3) : 376- 379.
  • 9Fiorica F, Cartei F, Ursino S, et al. Safety and feasi- bility of radiotherapy treatment in elderly non-small-cell lung cancer (NSCLC) patients [J]. Arch Gerontol, 2010,50 (2) : 185-191.
  • 10Paripati HR, Karlin NJ, Schild SE, et al. Multimodal- ity therapy improves survival in elderly patients with locally advanced non-small cell lung cancer-A retrospec- tive analysis[J]. Journal of Geriatric oneology, 2012,12 (3) : 104-110.

同被引文献132

  • 1刘宇龙,刘伟胜,徐凯,于雪梅.中药复方对肺癌术后患者免疫功能及远处转移的影响[J].浙江中医杂志,2005,40(2):69-71. 被引量:11
  • 2范亚光,姜勇,常润生,姚树祥,胡平,乔友林.职业高危人群肺癌病例胸部X线片和痰细胞学筛查结果分析[J].中国肺癌杂志,2007,10(2):102-106. 被引量:4
  • 3姚树祥,晋萍,范亚光,吴锡南,黄玉辉,杨兰,常润生,姚明鉴,乔友林.云南锡矿工人肺癌高发的流行病学调查(1954~2002年)[J].环境与职业医学,2007,24(5):465-468. 被引量:24
  • 4韦尉东,温浙盛,苏晓东,林鹏,戎铁华,陈丽昆.899例非小细胞肺癌完全切除术后的多因素生存分析[J].癌症,2007,26(11):1231-1236. 被引量:13
  • 5Kim JE. LeeDII. Choi Y. et al. Epidermal growth fac- tor receptor tyrosine kinase inhibitors as a first- line therapy for never - smokers with adenocarcinoma of the lung having asmptomatic synchronous brain merastasis[J]. Lung Cancer ,2009,65(3) :351.
  • 6TiseoM. Rossi G,CapellettiM. et al. Predictors of ge- fitiniboutcomes in advanced non- small cell lung cancer(NSCLC)., study of a comprehensive panel of molecular markers [J ]. Lung Cancer, 2010, 67 (3) .. 355 - 360.
  • 7耿振英,焦顺昌.2440例非小细胞癌临床分析.南开大学,2013.
  • 8Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008 : GLOBOCAN 2008 [ J ]. Int J Cancer, 2010,127 (12) :2893-2917.
  • 9Jemal A, Bray F, Center MM, et al. Global cancer statistics [ J ]. CA Cancer J Clin ,2011,61 ( 2 ) :69-90.
  • 10Garassino MC, Martelli O, Broggini M, et al. Erlotinib versus do- cetaxel as second-line treatment :of patients with advanced non- small-cell lung cancer and wild-type EGFR tumours (TAILOR) :a randomised controlled trial [ J ]. Lancet Oncol, 2013,14 ( 10 ) : 981-988.

引证文献14

二级引证文献110

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部